<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Capristo M</submitter><funding>Ministero della Salute</funding><funding>Telethon</funding><pagination>90</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9347137</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>28(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Myoclonus, Epilepsy and Ragged-Red-Fibers (MERRF) is a mitochondrial encephalomyopathy due to heteroplasmic mutations in mitochondrial DNA (mtDNA) most frequently affecting the tRNA&lt;sup>Lys&lt;/sup> gene at position m.8344A > G. Defective tRNA&lt;sup>Lys&lt;/sup> severely impairs mitochondrial protein synthesis and respiratory chain when a high percentage of mutant heteroplasmy crosses the threshold for full-blown clinical phenotype. Therapy is currently limited to symptomatic management of myoclonic epilepsy, and supportive measures to counteract muscle weakness with co-factors/supplements.&lt;h4>Methods&lt;/h4>We tested two therapeutic strategies to rescue mitochondrial function in cybrids and fibroblasts carrying different loads of the m.8344A > G mutation. The first strategy was ai</pubmed_abstract><journal>Molecular medicine (Cambridge, Mass.)</journal><pubmed_title>Rapamycin rescues mitochondrial dysfunction in cells carrying the m.8344A > G mutation in the mitochondrial tRNA&lt;sup>Lys&lt;/sup>.</pubmed_title><pmcid>PMC9347137</pmcid><funding_grant_id>GGP20115</funding_grant_id><pubmed_authors>Carelli V</pubmed_authors><pubmed_authors>Maresca A</pubmed_authors><pubmed_authors>Montopoli M</pubmed_authors><pubmed_authors>Caporali L</pubmed_authors><pubmed_authors>La Morgia C</pubmed_authors><pubmed_authors>Fiorini C</pubmed_authors><pubmed_authors>Capristo M</pubmed_authors><pubmed_authors>Tropeano CV</pubmed_authors><pubmed_authors>Del Dotto V</pubmed_authors><pubmed_authors>Valentino ML</pubmed_authors></additional><is_claimable>false</is_claimable><name>Rapamycin rescues mitochondrial dysfunction in cells carrying the m.8344A > G mutation in the mitochondrial tRNA&lt;sup>Lys&lt;/sup>.</name><description>&lt;h4>Background&lt;/h4>Myoclonus, Epilepsy and Ragged-Red-Fibers (MERRF) is a mitochondrial encephalomyopathy due to heteroplasmic mutations in mitochondrial DNA (mtDNA) most frequently affecting the tRNA&lt;sup>Lys&lt;/sup> gene at position m.8344A > G. Defective tRNA&lt;sup>Lys&lt;/sup> severely impairs mitochondrial protein synthesis and respiratory chain when a high percentage of mutant heteroplasmy crosses the threshold for full-blown clinical phenotype. Therapy is currently limited to symptomatic management of myoclonic epilepsy, and supportive measures to counteract muscle weakness with co-factors/supplements.&lt;h4>Methods&lt;/h4>We tested two therapeutic strategies to rescue mitochondrial function in cybrids and fibroblasts carrying different loads of the m.8344A > G mutation. The first strategy was ai</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Aug</publication><modification>2025-04-26T11:57:03.765Z</modification><creation>2025-02-18T22:39:49.99Z</creation></dates><accession>S-EPMC9347137</accession><cross_references><pubmed>35922766</pubmed><doi>10.1186/s10020-022-00519-z</doi></cross_references></HashMap>